Key clinical point: BNT162b2 SARS-CoV-2 mRNA (BioNTech Pfizer) vaccine is highly effective in patients with atopic dermatitis (AD), with no indication for alternate vaccination strategies among patients receiving immunosuppressants.
Major finding: Patients with AD who received both doses of BNT162b2 vaccine vs. those who were not vaccinated had a significantly reduced risk for SARS-CoV-2 infection (adjusted hazard ratio [aHR] 0.20), COVID-19-associated hospitalization (aHR 0.08), and COVID-19-associated mortality (aHR 0.04; all P < .001), with no impact of immunosuppressive drugs on vaccine efficacy against SARS-CoV-2 infection ( P = .958).
Study details: This population-based cohort study evaluated 77,682 adults with AD, of which 58,582 patients had completed two doses of BNT162b2 vaccine.
Disclosures: This study did not receive any funding. AD Cohen declared serving as an advisor, investigator, or speaker for several pharmaceutical companies.
Source: Kridin K et al. Determinants and effectiveness of BNT162b2 mRNA vaccination among patients with atopic dermatitis: A population-based study. Am J Clin Dermatol. 2022 (Mar 16). Doi: 10.1007/s40257-022-00672-5